LASSBio-1986 as a Multifunctional Antidiabetic Lead: SGLT1/2 Docking, Redox–Inflammatory Modulation and Metabolic Benefits in C57BL/6 Mice
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020829 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Landerson Lopes Pereira und 26 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Bioquímica e Farmacologia (LFB), Departamento de Farmacologia e Fisiologia, Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 1, Hypoglycemic Agents, Sodium-Glucose Transporter 2, Hydrazones. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tec-nológico, (CAPES), Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecno-logico.
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) involves chronic hyperglycemia, insulin resistance, low-grade inflammation, and oxidative stress that drive cardiometabolic and renal damage despite current therapies. Sodium–glucose cotransporter (SGLT) inhibitors have reshaped the treatment landscape, but residual risk and safety concerns highlight the need for new agents that combine glucose-lowering efficacy with redox–inflammatory modulation. LASSBio-1986 is a synthetic N-acylhydrazone (NAH) derivative designed as a gliflozin-like scaffold with the potential to interact with SGLT1/2 while also influencing oxidative and inflammatory pathways. Here, we integrated in silico and in vivo approaches to characterize LASSBio-1986 as a multifunctional antidiabetic lead in murine models of glucose dysregulation. PASS and target class prediction suggested a broad activity spectrum and highlighted transporter- and stress-related pathways. Molecular docking indicated high-affinity binding to both SGLT1 and SGLT2, with a modest energetic preference for SGLT2, and ADME/Tox predictions supported favorable oral drug-likeness. In vivo, intraperitoneal LASSBio-1986 improved oral glucose tolerance and reduced glycemic excursions in an acute glucose challenge model in C57BL/6 mice, while enhancing hepatic and skeletal muscle glycogen stores. In a dexamethasone-induced insulin-resistance model, LASSBio-1986 improved insulin sensitivity, favorably modulated serum lipids, attenuated thiobarbituric acid-reactive substances (TBARS), restored reduced glutathione (GSH) levels, and rebalanced pro- and anti-inflammatory cytokines in metabolic tissues, with efficacy broadly comparable to dapagliflozin. These convergent findings support LASSBio-1986 as a preclinical, multimodal lead that targets SGLT-dependent glucose handling while mitigating oxidative and inflammatory stress in models relevant to T2DM. Chronic disease models, formal toxicology, and pharmacokinetic studies, particularly with oral dosing, will be essential to define its translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Bioquímica e Farmacologia (LFB), Departamento de Farmacologia e Fisiologia, Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Faculdade de Medicina, Universidade Federal do Ceará, Rua Coronel N…
- Programa de Pós-Graduação em Ciências Naturais, Universidade Estadual do Ceará, Av. Dr. Silas Munguba, 1700, Fortaleza CEP 60714-903, Ceará, Brazil.
- Laboratório Farmacologia da Inflamação e do Câncer (LAFICA), Departamento de Farmacologia e Fisiologia, Núcleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Faculdade de Medicina, Universidade Federal do Ceará,…
- Departamento de Ciências Farmacêuticas, Instituto de Ciências Biológicas e da Saúde, Universidade Federal Rural do Rio de Janeiro (UFRRJ), Seropédica CEP 23890-000, Rio de Janeiro, Brazil.
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro CEP 21941-590, Rio de Janeiro, Brazil.
- Departamento de Análises Clínicas e Toxicológicas, Universidade Federal do Ceará, Fortaleza CEP 60430-160, Ceará, Brazil.
ORCID-Profile: Raimundo Rigoberto B Xavier Filho, Isabelle de Fátima Vieira Camelo Maia, Luis Gabriel Valdivieso Gelves, Damião Sampaio de Sousa, Régia Karen Barbosa De Souza, Paulo Iury Gomes Nunes, Gisele Silvestre Silva, Deysi Viviana Tenazoa Wong, Lidia Moreira Lima, Hélcio Silva Dos Santos, Emmanuel Silva Marinho, Kirley Marques Canuto, Pedro Filho Noronha Souza, Marisa Jadna Silva Frederico
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tec-nológico
- (CAPES)
- Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecno-logico
- CAPES/PPG-Pharmacology UFC
Zitieren
APA
Pereira, L. L., Filho, R. R. B. X., Freire, G. A., Martins, C. B. R., Perote, M. G. B., Campos, C. L. M., Monteiro, M. C. S., Maia, I. F. V. C., Lacerda, R. B., Gelves, L. G. V., Sousa, D. S., Souza, R. K. B., Nunes, P. I. G., Sampaio, T. L., Silva, G. S., Wong, D. V. T., Lima, L. M., Peláez, W. J., Marinho, M. M., …, & Frederico, M. J. S. (2026). LASSBio-1986 as a Multifunctional Antidiabetic Lead: SGLT1/2 Docking, Redox–Inflammatory Modulation and Metabolic Benefits in C57BL/6 Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020829
Vancouver
Pereira LL, Filho RRBX, Freire GA, Martins CBR, Perote MGB, Campos CLM, et al. LASSBio-1986 as a Multifunctional Antidiabetic Lead: SGLT1/2 Docking, Redox–Inflammatory Modulation and Metabolic Benefits in C57BL/6 Mice. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020829
BibTeX
@article{Pereira2026,
author = {Pereira, Landerson Lopes and Filho, Raimundo Rigoberto B Xavier and Freire, Gabriela Araújo and Martins, Caio Bruno Rodrigues and Perote, Maurício Gabriel Barros and Campos, Cibelly Loryn Martins and Monteiro, Manuel Carlos Serrazul and Maia, Isabelle de Fátima Vieira Camelo and Lacerda, Renata Barbosa and Gelves, Luis Gabriel Valdivieso and Sousa, Damião Sampaio de and Souza, Régia Karen Barbosa De and Nunes, Paulo Iury Gomes and Sampaio, Tiago Lima and Silva, Gisele Silvestre and Wong, Deysi Viviana Tenazoa and Lima, Lidia Moreira and Peláez, Walter José and Marinho, Márcia Machado and Santos, Hélcio Silva Dos and Menezes, Jane Eire Silva Alencar de and Marinho, Emmanuel Silva and Canuto, Kirley Marques and Souza, Pedro Filho Noronha and Morais, Francimauro Sousa and Alencar, Nylane Maria Nunes de and Frederico, Marisa Jadna Silva},
title = {LASSBio-1986 as a Multifunctional Antidiabetic Lead: SGLT1/2 Docking, Redox–Inflammatory Modulation and Metabolic Benefits in C57BL/6 Mice},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020829}
}
EUVIMED